Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + fruquintinib
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Serplulimab + fruquintinib is a combination therapy being investigated for the treatment of non-clear cell renal cell carcinoma (nccRCC). Serplulimab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor responses. Fruquintinib is a highly selective, potent oral small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which inhibits tumor-induced angiogenesis. The combination is currently being evaluated in a Phase III clinical trial sponsored by Sun Yat-sen University as an adjuvant therapy for patients with high-risk nccRCC following surgery, aiming to reduce the risk of recurrence by simultaneously enhancing immune activity and cutting off the tumor's blood supply.
- Other names
- serplulimab + fruquintinibHLX10 + HMPL-013Sullimumab + fruquintinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on serplulimab + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + fruquintinib.